Raised body weight and hypertension are locally relevant risk factors. Patients were examined in a Bavarian General Medicine Practice to investigate the relationship between raised body weight, hypertriglyceridemia and alcohol misuse with raised blood pressure or abnormal morning urines.
Methods:
The risk factors evaluated in this study of primary care patients were obesity, overweight, hypertriglyceridemia, self-reported alcohol misuse, raised blood pressure and proteinuria and/or hematuria in men (n = 86, 31 ± 12 years) and women (n = 160, 30 ± 10 years).
Results:
Men or women with obesity (BMI2) or alcohol misuse (AHA1) had significantly higher systolic or diastolic blood pressure and significantly lower HDL levels (p < 0.05) compared with men or women of normal weight or without alcohol problems and the ratio of serum albumin to triglycerides was significantly lower with obesity or alcohol misuse (p = 0.001, p = 0.001, respectively). Men with hypertriglyceridemia tended to be overweight and showed significantly higher blood pressure than men with normal triglyceride levels (p < 0.05). Obese men showed significantly higher diastolic blood pressure compared to obese women (p = 0.049). An increase in systolic (p = 0.0026) or diastolic (p = 0.0002) blood pressure was significantly associated with raised body weight (BMI1 + BMI2), while a rise in diastolic blood pressure was linked with alcohol misuse (p = 0.0005) using multivariate modelling. Proteinuria and/or hematuria in men's morning urine samples were significantly associated with misuse of alcohol or nicotine (p = 0.041, p = 0.045, respectively).
Conclusion:
The data showed significant associations between raised systolic or diastolic blood pressure and raised body weight. Raised diastolic blood pressure or proteinuria and/or hematuria were associated with misuse of alcohol and indicated a decline in renal endothelial barriers.
Get full access to this article
View all access options for this article.
References
1.
KristjanssonK., LjungmannS., BengtssonC., BjörkelundC., SigurdssonJ.A.Microproteinuria and long-term prognosis with respect to renal function and survival in normotensive and hypertensive women. Scand J Urol Nephrol, 2001; 35:63–70.
2.
PijlsL.T.J., de VriesH., KriegsmanD.M.W., DonkerA.J.M., van EijkJ.T.M.Determinants of albuminuria in people with Type 2 diabetes mellitus. Diab Res and Clin Practice, 2001; 52:133–143.
3.
HymanD.J., PavlikV.N.Characteristics of patients with uncontrolled hypertension in the United States. New Engl J Med, 2001; 345:479–496.
4.
WeissR., DziuraJ., BurgertT.S., TamborlaneW.V., TaksaliS.E., YeckelC.W., et al.Obesity and the Metabolic Syndrome in children and adolescents. New Engl J Med, 2004; 350:2362–2374.
5.
StuvelingE.M., HillegeH.L., BakkerS.J.L., AsselbergsF.W., de JongR.O., FansA., et al.Urine protein and microalbuminuria differ in their associations with various domains of vascular disease. Atherosclerosis, 2004; 172:107–114.
6.
BoermaM., ForsbergL., Van ZeijlL., MorgensternR., De FaireU., LemneC., et al.A genetic polymorphism in connexin 37 as a prognostic marker for atherosclerotic plaques development. J Int Medicine, 1999; 246:211–218.
7.
YamadaY., IzawaH., IchiharaS., TakatsuF., IshiharaH., HirayamaH., et al.Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. New Engl J Med, 2002; 347:1916–1923.
8.
FrostegardJ., HuangY.H., RönnelidJ., Schäfer-ElinderL.PAF and oxidized LDL induce immune activation by a common mechanism. Arterioscler Thromb Vasc Biol, 1997; 17:963–968.
9.
WuR., LemneC., De FaireU., FrostegardJ.Antibodies to platelet-activating factor are associated with borderline hypertension, early atherosclerosis and the metabolic syndrome. J Int Med, 1999; 246:389–397.
10.
KorthR., ZimmermannK., RichterW.Lipoprotein-associated paf (LA-paf) was found in washed human platelets and monocyte-macrophage-like U937 cells. Chem Phys Lipids, 1994; 70:109–119.
11.
HinesL.M., StampferM.J., MaJ., GazianoJ.M., RidkerP.M., HankinsonS.E., et al.Genetic variation in alcohol dehydrogenase and the beneficial effect of moderate alcohol consumption on myocardial infarction. New Engl J Med, 2001; 344:549–555.
12.
Marques-VidalP., MontayeM., HaasB., BinghamA., EvansA., Juhan-VagueI., et al.Relationships between alcoholic beverages and cardiovascular risk factor levels in middle-aged men, the PRIME study. Atherosclerosis, 2001; 157:431–440.
13.
InazuA., BrownM.L., HeslerC.B., AgellonL.B., KoizumiJ., TakataK., et al.Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. New Engl J Med, 1990; 323:12343–12348.
14.
LandsW.E.M.Cellular signals in alcohol-induced liver injury: a review. Alcohol Clin Exp Res, 1995; 19:928–938.
15.
KorthR.-M.Comparison of phosphocholines in human plasma and cerebrospinal fluid (CSF). Faseb J, 2000; 14:A72.
16.
KorthR.-M.Ether-linked phospholipids and hyperlipidemia. In: PandalaiS.G., editor. Recent Research Developments in Lipids, 5. Trivandium India: Transworld Research Network; 2001. p. 61–70.
KorthR.-M.Alcohol, obesity, hypertension and endothelial irritation. Faseb J, 2003; 17:A1140.
19.
KorthR., NunezD., BidaultJ., BenvenisteJ.Comparison of three paf-acether receptor antagonists ginkgolides. Eur J Pharmacol, 1988; 152:101–110.
20.
KorthR., HirafujiM., BenvenisteJ., Russo-MarieF.Human umbilical vein endothelial cells: Specific binding of platelet-activating factor and cytosolic calcium flux. Biochem Pharmacology, 1995; 49:1793–1799.
21.
KorthR.-M.Specific binding sites for 1-O-alkyl-sn-glyceryl-3-phosphorylcholine on intact human blood neutrophils. Int Arch Allergy Immunol, 1997; 113:460–464.
22.
KorthR., RiessH., BrehmG., HillerE.Unsaturated platelet-activating factor: influence on aggregation, serotonin release and thromboxane synthesis of human thrombocytes. Thrombosis Res, 1986; 41:699–706.
MaratheG.K., HarrisonK.A., RobertsJ.L., MorrowJ.D., MurphyR.C., TjoelkerL.W., et al.Identification of platelet-activating factor as the inflammatory lipid mediator in CCL4-metabolizing rat liver. J Lipid Res, 2001; 42:587–596.
25.
AnavekarN.S., McMurrayJ.J.V., VelazquezE.J., SolomonS.D., KoberL., RouleauJ.-L., et al.Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. New Engl J Med, 2004; 351:1285–1295.
26.
BerensonG.S., SrinivasanS.R., BaoW., NewmannW.P., TracyR.E., WattigneyW.A.Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. New Engl J Med, 1998; 338:1650–1656.
27.
KorthR.-M.Verwendung von paf-Acether-Antagonisten zur Herstellung eines Arzneimittels und Verfahren zu deren Wirksamkeitsbestimmung. Europäische Patentschrift, Publication No. 0312913, 1989.
28.
KorthR., MiddekeM.Long time incubation of monocytic U 937 cells with LDL increase specific PAF-acether binding and the cellular acetylhydrolase activity. Chem Phys Lipids, 1991; 59:207–213.
29.
IhidaK., PredescuD., CzekayR.P., PaladeG.E.Platelet activating factor receptor (PAF-R) is found in a large endosomal compartment in human umbilical vein endothelial cells. J Cell Science, 1999; 112:285–295.
30.
SnyderF.Metabolism of platelet activating factor and related ether lipids: enzymatic pathways, subcellular sites, regulation and membrane processing. In: AlanR., editor. Biological membranes: Aberrations in Membrane Structure and Function.. Liss Inc.; 1988. p. 57–72.
31.
MunnN.J., ArnioE., LiuD., ZoellerR.A., LiscumL.Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport. J Lipid Res, 2003; 44:182–192.
32.
CalleE., ThunM.J., PetrelliJ.M., RodriguezC., HeathC.Body mass index and mortality in a prospective Cohort of U.S. Adults. New Engl J Med, 1999; 341:1097–1105.
33.
WatanabeT., PakalaR., KatagiriT., BenedictC.R.Mildly oxidized low-density lipoprotein acts synergistically with angiotensin II in inducing vascular smooth muscle cell proliferation. J Hypertension, 2001; 19:1065–1073.
34.
VuongD., de KimpeS., de RoosR., RabelinkT.J., KoomansH.A., JolesJ.A.Albumin restores lysophosphatidylcholine-induced inhibition of vasodilation in rat aorta. Kidney Int, 2001; 60:1088–1096.
35.
BritesF.D., BonavitaC.D., de GeitereC., CloesM., DelflyB., YaelM.J., et al.Alterations in the main steps of reverse cholesterol transport in male patients with primary hypertriglyceridemia and low HDL-cholesterol levels. Atherosclerosis, 2000; 152:181–192.
36.
FournierN., FranconeO., RothblatG., GoudounecheD., CambillauM., Kellner-WeibelG., et al.Enhanced efflux from ABCA1-expressing macrophages to serum from type IV hypertriglyceridemic subjects. Atherosclerosis, 2003; 171:287–293.
37.
RamsamyT.A., BoucherJ., BrownR.J., YaoZ., SparksD.L.HDL regulates the displacement of hepatic lipase from cell surface proteoglycans and the hydrolysis of VLDL triacylglycerol. J Lipid Res, 2003; 44:733–741.
38.
KraemerF.B., ShenW.-J.Hormone-sensitive lipase: control of intracellular tri-(di)acylgylcerol and cholesteryl ester hydrolysis. J Lipid Res, 2002; 43:1585–1594.
